drugset / Trial / NCT06724900

A Study Assessing KB304 for the Treatment of Wrinkles in Women

NCT06724900 ↗

Phase 1/2 Active not recruiting 19 enrolled Krystal Biotech, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped chest area). KB304 is an investigational gene therapy that delivers functional, full-length human collagen (COL3) and elastin (tropoelastin) to the skin through small injections using the Sponsor's genetically engineered Herpes Simplex Virus (HSV-1) vector. The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inactive group).

Timeline

Start
2024-11-20
Primary completion
2025-07
Completion
2025-08

Drugs

EvaluationDrugModalityDoseRoute
Subject KB304 Unknown — —